Fiche centre
UZ Antwerpen
Edegem — Belgium
Essais liés10clinical trials
VilleEdegemlocalisation
PaysBelgiumlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06132893
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Zanidatamab | Cancer | Phase 3 | NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | RECRUITING |
| Soticlestat | Épilepsie | Phase 3 | NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | TERMINATED |
| Ocrelizumab | SEP | Phase 3 | NCT02861014 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06132893 | RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06660394 | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06719141 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | ACTIVE_NOT_RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06908226 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | ENROLLING_BY_INVITATION |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Mavenclad | SEP | À vérifier | NCT05797740 | Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA) | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01412333 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |